Cluster 2 (Figure 6, green cluster): The second study clustering contained 28 high-frequency keywords such as ranibizumab, macular degeneration, choroidal neovascularization (CNV), VEGF, anti-VEGF, intravitreal bevacizumab, avastin, pegaptanib, etc. This section focuses on the mechanism by which the ranibizumab treatment of nAMD reduces VEGF levels and inhibits CNV. This evidence concerns the gene VEGFA and choroidal neovascularization.